A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Hemay007
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Hemay 007 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; First in man
- Sponsors Hemay Pharmaceutical
- 23 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Mar 2018.
- 23 Oct 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
- 02 Jan 2017 Status changed from not yet recruiting to recruiting.